Trusted Resource for Clinical Trials, Protocols & Progress
One of the most significant obstacles in ASEAN clinical trials is the lack of regulatory harmonization. Although the ASEAN region is moving towards standardization through shared guidelines and the ASEAN Clinical Trials Network (ACTN), key challenges remain:
Click to read the full article.
In the ASEAN region, each country operates under its own regulatory authority responsible for clinical trial approvals. Some of the key agencies include:
Click to read the full article.
According to ICH-GCP and CDSCO standards, the following components are typically required in any informed consent form (ICF):
Click to read the full article.
Safety monitoring refers to the systematic tracking, documentation, analysis, and reporting of adverse events that occur during a clinical trial. The goal is to detect risk signals early, protect participants, and ensure compliance with international Good Clinical Practice (GCP) standards such as EMA and USFDA guidelines.
Click to read the full article.
Investigational Products are pharmaceutical forms of active ingredients or placebo being tested or used as a reference in a clinical trial. These include tablets, capsules, injectables, biologics, and vaccines. IPs must be handled with care, especially during cross-border transport, to ensure their identity, strength, quality, and purity remain intact.
Click to read the full article.
An Ethics Committee is an independent body tasked with reviewing, approving, and monitoring biomedical research involving human subjects. Their goal is to ensure that all ethical and legal aspects of the study are in compliance with the GMP guidelines and the ASEAN GCP framework.
Click to read the full article.
Originally adapted from ICH E6, the ASEAN GCP Guidelines serve as the ethical and scientific foundation for conducting clinical trials within the ten ASEAN member states. While countries like Singapore and Malaysia have advanced GCP systems, the ASEAN-wide GCP guidelines aim to harmonize standards for:
Click to read the full article.
The ASEAN bloc includes Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam—each with unique legal frameworks and health system capacities. The need for regulatory harmonization arises from:
Click to read the full article.
Southeast Asia comprises ten nations—Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam. Together, they represent a population of over 650 million and offer:
Click to read the full article.
The ASEAN region includes Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam. While each member state retains its own regulatory authority, ASEAN has initiated several efforts to harmonize standards across member countries to streamline cross-border research activities.
Click to read the full article.
